We appreciate the comments of Dr. De Boer and colleagues, who ask important questions about the effects of anticoagulant treatment and the characteristics of those patients who experienced thromboembolic events. As we mentioned in the article, it is difficult to accurately assess the effects of warfarin or aspirin in the SCD-HeFT database for several reasons, the most important of which being that such therapy was not randomized. 1 On entering the trial, 28% of the patients were taking warfarin and 59% were taking aspirin. These proportions changed substantially during the 45.5 months median follow-up; of those patients taking an antithrombotic agent at entry, 13% discontinued therapy and 14% switched from one type of agent to another over the course of the trial. Furthermore, neither the diagnosis of thromboembolic events nor the intensity of anticoagulant therapy was specified by protocol.
